BAI-BACE for Advanced Lung Squamous Cell Carcinoma

Status Recruiting

Clinical Trial Summary

Bronchial arterial infusion plus bronchial arterial chemoembolization (BAI-BACE) has been reported as non-first-line therapy to treat lung cancer in many hospitals in China. BAI, which uses chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor. Then BACE could seal off the tumor vessels. In this study, we aim to describe the efficacy and safety of BAI-BACE as non-first-line for advanced lung squamous cell carcinoma.

Clinical Trial Description

This study is a multicenter, interventional study to explore the efficacy, safety of BAI-BACE as non-first-line therapy for advanced central squamous cell carcinoma. Lung cancer is the leading cause of cancer-related death worldwide. Owing to the insidious symptom, most patients (about 75 %) are diagnosed at the advanced stage of the disease and, thus, cannot undergo resection. The central squamous cell carcinoma accounts for 25% of all cases of lung cancer. The first-line standard treatment for advanced central squamous cell carcinoma is combined chemoradiotherapy, and chemoradiotherapy is usually as the second-line. However, treatment failure is noted in many patients, and those patients often face the limited therapy choice and poor prognosis. Bronchial arterial infusion plus bronchial arterial chemoembolization (BAI-BACE) has been reported to treat lung cancer in many hospitals in China. BAI, which use chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor. Then BACE could seal off the tumor vessels. The systemic toxicity of this surgery is low and tolerable. This study will provide clinical evidence that BACE-BAI will provide survival benefit for patients with advanced central squamous cell carcinoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06377735
Study type	Interventional
Source	Sun Yat-sen University
Contact	Qunfang Zhou, MD
Phone	86 19868000115
Email	zhouqun988509@163.com
Status	Recruiting
Phase	N/A
Start date	May 1, 2024
Completion date	December 30, 2026

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02213133` - Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas	Phase 2
Not yet recruiting	`NCT04533321` - A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma	Phase 2
Terminated	`NCT02890368` - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides	Phase 1
Active, not recruiting	`NCT01232374` - Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma	Phase 2
Withdrawn	`NCT01148082` - School Response to Families Who Have Children With Cancer	N/A
Completed	`NCT01208883` - A Feasibility Study On Continuous Adaptive [18f]Fdg-Pet-Guided Radiotherapy For Head and Neck Cancer	Phase 1
Completed	`NCT01089803` - Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer	N/A
Terminated	`NCT00707655` - Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy	Phase 1/Phase 2
Completed	`NCT00793169` - Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
Completed	`NCT00586040` - Photochemical Tissue Bonding	Phase 2
Completed	`NCT01127737` - Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients	N/A
Completed	`NCT00409565` - A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer	Phase 2
Completed	`NCT00176267` - Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer	Phase 2
Terminated	`NCT04685798` - Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT	N/A
Recruiting	`NCT04370587` - A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04475952` - Early Diagnosis of Upper Digestive Tract Disease
Recruiting	`NCT04435938` - A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck	Phase 2
Not yet recruiting	`NCT05852665` - Buccal Cancer Resection Ultrasound Guided	N/A
Recruiting	`NCT05048459` - Comparing Two Surveillance Approaches for People Who Have Received Treatment for HPV-associated Head and Neck Cancer and Show No Signs of Disease	N/A
Suspended	`NCT03952585` - De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer	Phase 2/Phase 3